SGS Life Sciences Services to host 4th Antwerp Biopharm Seminar on clinical trial solutions
The one-day conference, entitled “Safety and Efficacy — Clinical Trials Solutions”, will bring together experts from SGS Life Services and the wider pharmaceutical industry, to discuss advances in biopharmaceutical research and development and combine a number of scientific talks, case studies and face-to-face meetings to highlight the most recent solutions in clinical development optimization.
SGS Life Science Services is to host a complimentary Biopharm Day in Antwerp, Belgium. The event, building on the success of previous years’ events, is to be held at the Lindner Hotel, on Thursday, 29 October 2015. The one-day conference, entitled “Safety and Efficacy — Clinical Trials Solutions”, will bring together experts from SGS Life Services and the wider pharmaceutical industry, to discuss advances in biopharmaceutical research and development and combine a number of scientific talks, case studies and face-to-face meetings to highlight the most recent solutions in clinical development optimization.
Joining SGS Life Science Services experts will be Ingeborg Heirman, Business Development Manager of VIB vzw, who will explain the role VIB plays in bridging academia with pharma/biotech companies and clinical research organizations, to further development of innovative drugs and biomarkers/diagnostic assays; Gary Kay, CEO of Cognitive Research Corporation, who will present on the 2015 FDA Draft Guidance on evaluating drug effects on driving; and Dr Jean François Rossignol, co-founder, Chief Scientific Officer and Chairman of Romark Laboratories, who will present a case study on influenza vaccine development. A tour of SGS Life Science Services’ Clinical Pharmacology Unit will be organized following the closing remarks. “The clinical research field has many challenges and opportunities which face both sponsors and service providers,” commented Jean-Luc Marsat, Business Manager at SGS Life Science Services. “By bringing together our clients and leading industry experts, and sharing experiences and knowledge in an open forum, we aim to give valuable insight into new trends and practices in biopharmaceutical research and development from a wide range of industry perspectives.”
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance